Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders

Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net ...

Theravance Biopharma, Inc.: Theravance Biopharma Enters Into Definitive Agreement To Be Acquired By Zymeworks For $17.00 Per Share In Cash Plus A Contingent Value Right

Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders ...